116 related articles for article (PubMed ID: 20693974)
1. Multidisciplinary approach in diagnosis of lung carcinoma.
Kontic M; Stojsic J; Kacar-Kukric V; Jekic B; Bunjevacki V
Exp Oncol; 2010 Jul; 32(2):111-3. PubMed ID: 20693974
[TBL] [Abstract][Full Text] [Related]
2. Primary large-cell neuroendocrine carcinoma of the parotid gland: immunohistochemical and molecular analysis of two cases.
Nagao T; Sugano I; Ishida Y; Tajima Y; Munakata S; Asoh A; Yamazaki K; Muto H; Konno A; Kondo Y; Nagao K
Mod Pathol; 2000 May; 13(5):554-61. PubMed ID: 10824928
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite instability in large cell neuroendocrine carcinoma of the female genital tract.
Mhawech-Fauceglia P; Chan A; Keitz B; Lele S; Cheney RT; Starostik P
Histopathology; 2009 Nov; 55(5):621-5. PubMed ID: 19912372
[No Abstract] [Full Text] [Related]
4. Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays.
Wikman H; Seppänen JK; Sarhadi VK; Kettunen E; Salmenkivi K; Kuosma E; Vainio-Siukola K; Nagy B; Karjalainen A; Sioris T; Salo J; Hollmén J; Knuutila S; Anttila S
J Pathol; 2004 May; 203(1):584-93. PubMed ID: 15095482
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of loss of heterozygosity in large cell neuroendocrine carcinomas of the lung and small cell lung carcinomas.
Takeuchi T; Minami Y; Iijima T; Kameya T; Asamura H; Noguchi M
Pathol Int; 2006 Aug; 56(8):434-9. PubMed ID: 16872437
[TBL] [Abstract][Full Text] [Related]
6. Tumors in the lung--morphologic features and the challenge of integrating biomarker signatures into diagnostics.
Vollmer E; Schultz H; Stellmacher F; Kähler D; Abdullah M; Galle J; Lang DS; Goldmann T
Rom J Morphol Embryol; 2010; 51(4):607-14. PubMed ID: 21103615
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel.
Nitadori J; Ishii G; Tsuta K; Yokose T; Murata Y; Kodama T; Nagai K; Kato H; Ochiai A
Am J Clin Pathol; 2006 May; 125(5):682-92. PubMed ID: 16707368
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma.
Hiroshima K; Iyoda A; Shibuya K; Haga Y; Toyozaki T; Iizasa T; Nakayama T; Fujisawa T; Ohwada H
Cancer; 2004 Mar; 100(6):1190-8. PubMed ID: 15022286
[TBL] [Abstract][Full Text] [Related]
9. Large cell/neuroendocrine carcinoma.
Gollard R; Jhatakia S; Elliott M; Kosty M
Lung Cancer; 2010 Jul; 69(1):13-8. PubMed ID: 20133008
[TBL] [Abstract][Full Text] [Related]
10. Abnormal p53 expression in lung neuroendocrine tumors. Diagnostic and prognostic implications.
Roncalli M; Doglioni C; Springall DR; Papotti M; Pagani A; Polak JM; Ibrahim NB; Coggi G; Viale G
Diagn Mol Pathol; 1992 Jun; 1(2):129-35. PubMed ID: 1364172
[TBL] [Abstract][Full Text] [Related]
11. High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma.
Sun L; Sakurai S; Sano T; Hironaka M; Kawashima O; Nakajima T
Pathol Int; 2009 Aug; 59(8):522-9. PubMed ID: 19627535
[TBL] [Abstract][Full Text] [Related]
12. Achaete-scute homolog 1 as a marker of poorly differentiated neuroendocrine carcinomas of different sites: a validation study using immunohistochemistry and quantitative real-time polymerase chain reaction on 335 cases.
La Rosa S; Marando A; Gatti G; Rapa I; Volante M; Papotti M; Sessa F; Capella C
Hum Pathol; 2013 Jul; 44(7):1391-9. PubMed ID: 23375646
[TBL] [Abstract][Full Text] [Related]
13. Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas.
Nagashio R; Sato Y; Matsumoto T; Kageyama T; Satoh Y; Ryuge S; Masuda N; Jiang SX; Okayasu I
Pathol Int; 2010 Feb; 60(2):71-7. PubMed ID: 20398190
[TBL] [Abstract][Full Text] [Related]
14. [Case report No.142: large cell lung cancer accompanied by remarkable leukocytosis and hypercarcinoma].
Kato H; Kageshita T; Miyatake H; Shimizu M; Nagao M; Fujita M; Yuu H; Maeda S
Clin Calcium; 2004 Jun; 14(6):142-6. PubMed ID: 15577069
[No Abstract] [Full Text] [Related]
15. Small large-cell neuroendocrine carcinoma in a patient with pulmonary emphysema.
Kagohashi K; Satoh H; Kurishima K; Kikuchi N; Ishikawa H; Sekizawa K
Tuberk Toraks; 2009; 57(1):77-80. PubMed ID: 19533442
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas.
Lyda MH; Weiss LM
Hum Pathol; 2000 Aug; 31(8):980-7. PubMed ID: 10987260
[TBL] [Abstract][Full Text] [Related]
17. [Clinical application of molecular oncology].
Akita H
Hokkaido Igaku Zasshi; 2003 Jan; 78(1):3-5. PubMed ID: 12613017
[No Abstract] [Full Text] [Related]
18. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
20. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis.
Takahashi T; Munakata M; Ohtsuka Y; Nisihara H; Nasuhara Y; Kamachi-Satoh A; Dosaka-Akita H; Homma Y; Kawakami Y
Cancer; 2002 Aug; 95(3):624-33. PubMed ID: 12209756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
